Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat
Mar 1, 2022
1 min read
Updated: Sep 13, 2022
Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk, high-reward IL-12 target — doing it in a deal with repeat collaborator and NK cell engager player Dragonfly Therapeutics.
As part of that deal, Vessey handed over $475 million in near-term cash in exchange for a global license for Dragonfly’s extended half-life cytokine DF6002 — a monovalent, IL-12 immunoglobulin Fc fusion protein designed to spur a targeted immune response.
Really interesting to see how that $475 million upfront for DF6002 is playing out — the monovalent IL-12 Fc fusion design always felt like a high-stakes bet, and the "Vessey's turn at bat" framing makes it feel personal. Hope the early DF5112 data keeps the momentum going. By the way, I keep a free fancy text generator and Unicode inspector that turns plain text into 23 stylish Unicode fonts (bold, script, fraktur) and cleans hidden or invisible characters I like to share: https://glyphsift.com/
It's impressive how Bristol Myers Squibb and Dragonfly Therapeutics have made significant strides in IL-12 research. To ensure ethical AI usage, consider removing AI metadata with Remove AI Metadata for transparency.
Insightful post on Bristol-Myers' IL-12 work -great breakdown of the scientific and operational challenges. For teams managing the large clinical datasets behind these studies, this clear primer on SQL Server partitioning can really speed up queries and simplify ETL: https://devcom.com/tech-blog/how-to-partition-a-table-in-sql-server/
This is a good one! Thank you for writing and sharing this.
the freak circus
Great blog which has shared really very fantastic.
volume shader